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A series of novel drugs targeting growth factor signaling –
including antibodies targeting growth factors or their
receptors, low-molecular weight tyrosine kinase (TK)
inhibitors and mTOR inhibitors – are approved as cancer
drugs. These drugs differ with regard to target cells and tar-
get molecules. Best effects of drugs targeting TKs on malig-
nant cells are, in general, observed in tumors where target
TK is activated by amplification, translocation or point-
mutations. Mutational activation of down stream signal-
ing proteins, such as PI3 kinase or RAS, is associated with
reduced sensitivity to TK-targeting drugs. Determinants of
resistance and sensitivity to anti-angiogenic drugs remain
mostly unknown. Results from breast cancer suggest that
many of these drugs will display highest efficacy when
used in adjuvant settings.
Our studies on the role of PDGF receptor signaling in can-
cer have revealed important roles of autocrine PDGF
receptor signaling in dermatofibrosarcoma protuberans
and glioblostoma. However, in common solid tumors,
PDGF receptor signaling is predominantly involved in the
regulation of tumor stroma through effects on pericytes
and cancer-associated fibroblasts (CAFs). Studies in ani-
mal models have demonstrated that inhibition of stromal
PDGF-receptors improves tumor drug uptake, and thus
suggest a novel rational for combination treatments with
PDGF inhibitors and other cancer drugs. Recent analyses
of large series of human breast cancer have also identified
high stromal PDGF receptor expression as a marker for
worse prognosis.
Ongoing studies in our group also aim at identification of
novel stroma-derived cancer drug targets. By gene expres-
sion profiling of prostate CAFs we have identified
CXCL14 as a novel CAF-derived multi-modal stimulator
of tumor growth. Ongoing studies also explore how para-
crine crosstalk between CAFs and malignant cells, will
affect the proliferation, migration and drug response of
malignant cells.
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